Merus to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced CEO Bill Lundberg's participation in several upcoming investor conferences. Key events include a panel discussion at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, a pre-recorded presentation at H.C. Wainwright 23rd Annual Global Investment Conference available on September 13, and a presentation at the 2021 Cantor Virtual Global Healthcare on September 27, 2021. The webcasts will be accessible on the company's investor page, with archived presentations available for a limited time.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences:

• Citi’s 16th Annual BioPharma Virtual Conference (Panel discussion): Thursday, Sept. 9, 2021 at 1:25-2:25 p.m. ET
• H.C. Wainwright 23rd Annual Global Investment Conference (Presentation): Pre-recorded and available starting September 13 at 7:00 a.m. ET
• 2021 Cantor Virtual Global Healthcare (Presentation): Monday, September 27, 2021 at 2:40-3:10 p.m. ET
  

The webcast of the presentations will be available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

FAQ

What conferences is Merus N.V. CEO Bill Lundberg attending in September 2021?

Bill Lundberg will attend Citi’s 16th Annual BioPharma Virtual Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, and the 2021 Cantor Virtual Global Healthcare on September 27, 2021.

What is the stock symbol for Merus N.V.?

The stock symbol for Merus N.V. is MRUS.

When will the presentations from Merus N.V.'s investor conferences be available?

The presentations will be available live during the conferences and archived for a limited time on Merus N.V.'s Investors page.

What type of therapies is Merus N.V. developing?

Merus N.V. is developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Biclonics and Triclonics.

Where can I find more information about Merus N.V.'s events?

More information about Merus N.V.'s events can be found on their official website and under the Investors page.